Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA)

Barclays PLC boosted its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 777.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,061 shares of the company’s stock after buying an additional 56,757 shares during the quarter. Barclays PLC owned approximately 0.10% of Zura Bio worth $260,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZURA. Braidwell LP acquired a new position in shares of Zura Bio during the 3rd quarter worth approximately $10,040,000. Point72 Asset Management L.P. acquired a new position in shares of Zura Bio in the second quarter valued at $8,446,000. Great Point Partners LLC raised its position in shares of Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the period. Armistice Capital LLC lifted its stake in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after buying an additional 876,000 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Zura Bio during the 3rd quarter worth about $2,999,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

Zura Bio stock opened at $1.77 on Tuesday. The stock’s fifty day moving average price is $2.63 and its two-hundred day moving average price is $3.49. Zura Bio Limited has a one year low of $1.76 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, equities research analysts forecast that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Insider Activity

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 22.10% of the company’s stock.

Analyst Upgrades and Downgrades

ZURA has been the topic of several research analyst reports. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Leerink Partners began coverage on Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 target price on the stock. Chardan Capital reduced their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $15.80.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.